Key Findings
The global neurostimulation device market which was worth $XX million in 2018 is anticipated to grow at a CAGR of 10.01% during the forecast period of 2019-2027. Its net worth is estimated to rise to $XX million by the end of 2027. The fact that these devices aid in the therapeutic activation for many neurological diseases is majorly driving the market. Other factors include the high occurrence of diseases, second-line of treatment, increased elderly populace and the various developments in technology.

Market Insights
The global neurostimulation device market can be segmented by the type of system and by the application type. The different type of systems can be classified as Global DBS system market, Global SCS system market, Global SNS system market, Global VNS system market and others. The application of the neurostimulation devices can be seen in Depression market, Pain management market, Essential tremor market, Epilepsy market, Urinary and fecal incontinence market, Dystonia market, Gastroparesis market and in Parkinson’s disease market. Albeit such a wide range of applications, safety concerns remain to be one of the major market challenges. Patients might be at risk of contracting infections at the time of implantation or may face issues if they are in contact with or near to electromagnetic radiation and electrical and gas-powered appliances. Also, the malfunction of the implanted device might go unnoticed by the patient leading to higher risks.

Regional Insights
Geographically, the market can be divided into four major regions, namely, North America, Asia Pacific, Europe and the Rest of the World. The Asia-Pacific market is predicted to show the fastest growth over the forecast period. Factors like a large patient base and the rising investments in healthcare sectors in countries like China and Japan are proving conducive to the market growth in this region. At present, however, the North America region is leading the market scene. The United States is a major revenue contributor to the global neurostimulation device market. The North American region is expected to continue this dominance and hold the highest share by 2025 in the global market. The market is wildly attracting investors from all over the globe because of profitable aspects like advances in technology and the US government’s increased focus on improving patient safety and procedure efficiency by using neurostimulation devices.

Competitive Insights
St. Jude Medical is a global medical device manufacturer that develops medical technology, products, and services for the treatment of neurological, chronic pain, and cardiac patients. Another company, Boston Scientific caters to high-quality medical devices used in the treatment of a large number of medical conditions. Medtronic Inc. manufactures and sells device-centered medicinal treatments globally along with assembling intra-operative imaging systems and image-guided surgery. It also offers web-based therapy management software solutions. The other major players in the market are Cogentix Medical Inc., St. Jude Medical Inc. (acquired by Abbott Laboratories), Aleva Neurotherapeutics SA, Boston Scientific Corporation, Helius Medical Technologies, The Magstim Company Limited, Cyberonics Inc., Neuronetics Inc., Depuy Synthes Companies, Ekso Bionics Holding Inc., Medtronic PLC, Dr. Langer Medical GmBH, Ectron Limited, Nevro Corp. and Hocoma AG